Home › Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...
 

Keywords :   


Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...

2016-03-07 18:44:11| Biotech - Topix.net

Regeneron reported disappointing full-year 2015 results in early February, and once booming sales of EYLEA are starting to finally exhibit some sluggishness. The company's heavily-anticipated PCSK9 drug, Praluent, launched in mid-2015, but has yet to exhibit sales that were expected from the potential billion-dollar rock star.

Tags: short ahead downside bloated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05Melting Massage Bar Patented by Johnson & Johnson
03.05How the computer games industry is embracing AI
03.05Apple sees biggest fall in sales for a year
02.05Turkey halts trade with Israel over Gaza 'tragedy'
02.05Loop Industries and Ester Ltd. Announce Joint Venture
02.05The Oldham Group names Hunter Collins account manager
02.05NCBAs Sigrid Johannes promoted to Senior Director of Government Affairs
02.05University helps neighboring ranchers oust redcedars
More »